China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
12/05/2026 05:16
May 12 (Reuters) - China's Jiangsu Hengrui Pharmaceuticals 1276.HK 600276.SS said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb BMY.N to develop 13 early‑stage oncology, hematology and immunology programmes, with potential milestone payments of up to $15.2 billion. (Reporting by Roushni Nair in Bengaluru) ((Roushni.Nair@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC